Ken Griffin’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.56M | Sell |
38,887
-609,342
| -94% | -$13.1M | ﹤0.01% | 6621 |
|
|
2025
Q4 | $16.3M | Buy |
648,229
+61,777
| +11% | +$1.45M | ﹤0.01% | 2612 |
|
|
2025
Q3 | $13.3M | Buy |
586,452
+143,892
| +33% | +$3.36M | ﹤0.01% | 2862 |
|
|
2025
Q2 | $7.66M | Buy |
442,560
+218,464
| +97% | +$4.04M | ﹤0.01% | 3418 |
|
|
2025
Q1 | $4.9M | Buy |
224,096
+111,673
| +99% | +$3.08M | ﹤0.01% | 3904 |
|
|
2024
Q4 | $3.59M | Sell |
112,423
-85,710
| -43% | -$2.58M | ﹤0.01% | 4525 |
|
|
2024
Q3 | $5.71M | Buy |
198,133
+44,242
| +29% | +$1.64M | ﹤0.01% | 3742 |
|
|
2024
Q2 | $5.9M | Sell |
153,891
-1,032,191
| -87% | -$46.7M | ﹤0.01% | 3493 |
|
|
2024
Q1 | $69.7M | Buy |
1,186,082
+900,965
| +316% | +$57.4M | 0.01% | 964 |
|
|
2023
Q4 | $17.1M | Buy |
285,117
+270,370
| +1,833% | +$13.7M | ﹤0.01% | 2174 |
|
|
2023
Q3 | $561K | Sell |
14,747
-513,825
| -97% | -$22.6M | ﹤0.01% | 7814 |
|
|
2023
Q2 | $48.2M | Buy |
528,572
+354,512
| +204% | +$30.6M | 0.01% | 1087 |
|
|
2023
Q1 | $11.5M | Buy |
174,060
+168,791
| +3,203% | +$9.74M | ﹤0.01% | 2616 |
|
|
2022
Q4 | $272K | Sell |
5,269
-42,892
| -89% | -$2.28M | ﹤0.01% | 9525 |
|
|
2022
Q3 | $3.29M | Sell |
48,161
-149,298
| -76% | -$8.83M | ﹤0.01% | 4624 |
|
|
2022
Q2 | $8.93M | Sell |
197,459
-231,793
| -54% | -$10.6M | ﹤0.01% | 2844 |
|
|
2022
Q1 | $21.8M | Sell |
429,252
-524,479
| -55% | -$23.2M | ﹤0.01% | 1885 |
|
|
2021
Q4 | $45.1M | Sell |
953,731
-904,701
| -49% | -$35.6M | 0.01% | 1250 |
|
|
2021
Q3 | $61.3M | Buy |
1,858,432
+1,505,416
| +426% | +$84.6M | 0.01% | 971 |
|
|
2021
Q2 | $22.3M | Buy |
353,016
+300,464
| +572% | +$15.5M | 0.01% | 1946 |
|
|
2021
Q1 | $2.25M | Sell |
52,552
-1,384,394
| -96% | -$65.5M | ﹤0.01% | 6109 |
|
|
2020
Q4 | $82.2M | Sell |
1,436,946
-765,312
| -35% | -$32.4M | 0.02% | 657 |
|
|
2020
Q3 | $66.4M | Buy |
2,202,258
+832,498
| +61% | +$24.9M | 0.02% | 681 |
|
|
2020
Q2 | $44.7M | Buy |
1,369,760
+634,920
| +86% | +$20.4M | 0.02% | 872 |
|
|
2020
Q1 | $19.7M | Buy |
734,840
+178,480
| +32% | +$6.34M | 0.01% | 1246 |
|
|
2019
Q4 | $17M | Buy |
+556,360
| New | +$15.4M | 0.01% | 1635 |
|
|
2019
Q3 | – | Sell |
-641,720
| Closed | -$16.3M | – | 9123 |
|
|
2019
Q2 | $16.3M | Sell |
641,720
-303,464
| -32% | -$6.17M | 0.01% | 1630 |
|
|
2019
Q1 | $18.4M | Buy |
945,184
+894,915
| +1,780% | +$14.1M | 0.01% | 1414 |
|
|
2018
Q4 | $663K | Sell |
50,269
-13,443
| -21% | -$206K | ﹤0.01% | 5960 |
|
|
2018
Q3 | $1.13M | Buy |
63,712
+52,445
| +465% | +$969K | ﹤0.01% | 5324 |
|
|
2018
Q2 | $247K | Buy |
+11,267
| New | +$259K | ﹤0.01% | 7541 |
|
Other funds holding APLS
ACA
VPM
PCM
VCM
DTC
Ken Griffin's APLS Position: Q1 2026 in Review
Ken Griffin reduced its Apellis Pharmaceuticals (APLS) stake by 94% in Q1 2026, selling an estimated $13.1M and leaving 38,887 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #6621.
Ken Griffin first reported a position in APLS in Q2 2018 and has held it in 31 quarters since. The position peaked at $82.2M in Q4 2020. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.
- Ken Griffin held 38,887 shares of Apellis Pharmaceuticals worth $1.56M as of Q1 2026.
- Ken Griffin sold 609,342 Apellis Pharmaceuticals shares in Q1 2026, an estimated $13.1M.
- Apellis Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #6621 holding.
- Ken Griffin first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
- Ken Griffin's Apellis Pharmaceuticals position peaked at $82.2M in Q4 2020.
- 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.